MEGF8

Across TCGA pan-cancer cohorts, MEGF8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MEGF8 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MEGF8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MEGF8 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where MEGF8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.202	0.978	.011	22	view →
UCEC	OS	Median	All	0.903	1.000	.007	16	view →
LUAD	DFS	Median	All	0.849	0.957	.027	14	view →
LSCC	DFS	Median	All	0.833	0.603	.011	12	view →
PDAC	OS	Tertile	All	0.524	0.906	.004	10	view →
GBM	OS	Tertile	All	0.258	0.602	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MEGF8–CCRCC (OS)

Open the CCRCC breakdown →